Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056830 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
A Phase 3 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Clarity Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
- 20
- Study locations
NCT06056830: Recruiting Phase 3 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Clarity Pharmaceuticals.
NCT06056830 is a Phase 3 study of Prostate Cancer and Prostatic Neoplasms that is actively recruiting participants, run by Clarity Pharmaceuticals. The registered enrollment target is 383 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06056830, a Phase 3 study of Prostate Cancer and Prostatic Neoplasms, is actively recruiting participants, sponsored by Clarity Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Primary Outcome
Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.
Conditions Studied
Interventions
- DRUG 64Cu-SAR-bisPSMA
Study Locations (20)
California
- Urology Group of Southern California - Los Angeles
- Greater Los Angeles VA Medical Center - Los Angeles
- Stanford University Medical Center - Stanford
Florida
- Mayo Clinic- Jacksonville - Jacksonville
- Biogenix Molecular, LLC - Miami
Michigan
- BAMF Health - Grand Rapids
- Corewell Health - Grand Rapids
Alabama
- University of Alabama Birmingham Hospital - Birmingham
Arizona
- Mayo Clinic- Phoenix - Phoenix
Illinois
- NorthShore University Health System - Glenview
Indiana
- Indiana University School of Medicine - Indianapolis
Minnesota
- Mayo Clinic- Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What NCT06056830 shows while recruiting
NCT06056830 is an interventional study that assigns participants to a tested intervention. The registered 383 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 64Cu-SAR-bisPSMA is the first listed.
NCT06056830 names 20 study sites across 16 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06056830 about?
NCT06056830 is a clinical study titled "Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy". The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
What is the current status of trial NCT06056830?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2023-12-21. Estimated completion is 2026-09.
What conditions does trial NCT06056830 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms.
What interventions are being tested in trial NCT06056830?
The interventions under investigation include: 64Cu-SAR-bisPSMA (DRUG).
Who is sponsoring clinical trial NCT06056830?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06056830 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06056830's enrollment target sits among peer trials
383 141st of 735 higher than 595 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
- NCT06566703 · 384 participants · NA
Testing ANSOS for Efficacy in Multi-Tribal Urban Communities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI